Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumours (MK-4280-001)

Official Title

A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Summary:

This is a safety and pharmacokinetics study of MK-4280 as monotherapy and in combination with pembrolizumab (MK-3475) in adults with metastatic solid tumours for which there is no available therapy which may convey clinical benefit. Part A of this study is a dose escalation design in which participants receive MK-4280 as monotherapy or MK-4280 in combination with pembrolizumab. Part B is a dose confirmation design to estimate the recommended Phase 2 dose (RPTD) for MK-4280 in combination with pembrolizumab in participants with advanced solid tumours.

Trial Description

Primary Outcome:

  • Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
  • Number of Participants Who Experience at Least One Adverse Event (AE)
  • Number of Participants Who Discontinue Study Drug Due to an AE
Secondary Outcome:
  • Objective Response Rate (ORR) as Determined by Response Evaluation Criteria in Solid Tumours (RECIST 1.1) as Assessed by Investigator Review of MK-4280 in Combination With Pembrolizumab at the RPTD
  • ORR as Determined by RECIST 1.1 as Assessed by Investigator Review of Two Doses of MK-4280 in Combination With Pembrolizumab for Participants with Advanced Solid Tumours
  • Serum Concentration of MK-4280 When Administered as Monotherapy and as Combination Therapy with Pembrolizumab
  • Serum Concentration of Pembrolizumab When Administered in Combination with MK-4280 - Combination Therapy Arms Only

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society